Merz offers Xeomin users financial assistance with new programs

GREENSBORO, N.C. — Merz Pharmaceuticals has created two programs to provide financial assistance to patients using its drug for cervical dystonia, the company said Tuesday.

The programs — the Xeomin patient co-payment program and the Xeomin patient assistance program — cover Xeomin (incobotulinumtoxinA), designed to decrease the severity of abnormal head positions and neck pains in patients with the disease, which causes muscle contractions resulting in repetitive movements and abnormal postures.

“By offering a continuum of Xeomin financial assistance programs, our hope is to help patients manage their cervical dystonia and blepharospasm costs by reducing or eliminating financial obstacles that may prevent initiation or continuation of treatment,” said Merz president and CEO Jack Britts.